IL-17抑制剂治疗患者中新发炎症性肠病:MISSIL病例对照研究结果
基于法国国家注册登记MISSIL,收集2016年1月至2019年12月IL-17抑制剂治疗中新发IBD病例31例(脊柱关节炎27例、银屑病4例,均为司库奇尤单抗),中位发病时间4.0个月,年发病率从2016年0.69/100患者年降至2019年0.08/100患者年,24/31例转归良好但2例死亡。
要点
- 31例新发IBD均见于司库奇尤单抗治疗者,中位发病时间4.0个月。
- 年发病率从2016年0.69/100患者年降至2019年0.08/100患者年。
- 未既往使用依那西普及既往生物制剂种类少与新发IBD显著相关。
核心结论
- IL-17抑制剂治疗中新发IBD发病率低,且从2016年至2019年下降。
- 31例中24例转归良好,但2例死亡。
研究设计与样本
- 法国国家注册登记MISSIL,收集2016年1月至2019年12月IL-17抑制剂治疗中新发IBD病例。
- 利用法国研究期间IL-17抑制剂治疗患者估计数计算年发病率。
- 采用病例对照研究,每例新发IBD病例按性别、年龄和基础炎症性疾病匹配2例对照。
主要发现
- 共收集31例IL-17抑制剂治疗中新发IBD:27例治疗脊柱关节炎,4例治疗银屑病。
- 全部31例均在使用司库奇尤单抗(SEK)时观察到。
- 新发IBD症状中位发病时间为4.0(1.5-7.5)个月。
- 所有患者均停用SEK,转归为完全缓解17/31、改善7/31、稳定5/31。
- 2例死亡:1例死于大面积心肌梗死,1例死于结肠切除术后并发症。
关键数值与推荐
- 新发IBD年发病率:2016年0.69/100患者年(7/1010),2019年0.08/100患者年(6/7951)。
- 未既往使用依那西普与新发IBD相关:OR=0.33(95%CI:0.14-0.80,P=0.014)。
- 既往生物制剂治疗种类少与新发IBD相关:OR=0.67(95%CI:0.47-0.94,P=0.021)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To describe new-onset IBD (new IBD) in patients treated with IL-17 inhibitors (IL-17i), to assess their incidence and to identify their risk factors in real life. METHODS: A French national registry (MISSIL) aimed to report all cases of new IBD in patients treated with IL-17i from January 2016 to December 2019. Using the estimated number of patients treated by IL-17 in France during the study period, the annual incidence rates of new IBD was reported in IL-17i-treated patients. A case-control study was performed with two controls per new IBD case matched by gender, age and underlying inflammatory disease. RESULTS: Thirty-one cases of new IBD under IL-17i were collected: 27 patients treated for spondyloarthritis and four patients for psoriasis. All were observed with secukinumab (SEK). The median time to onset of new IBD symptoms was 4.0 (1.5-7.5) months. SEK was discontinued in all patients. The evolution was favourable with complete resolution (17/31), improvement (7/31) or stabilization (5/31). Two patients died: one due to a massive myocardial infarction and one due to post-colectomy complications. The incidence of new IBD decreased from 0.69/100 patient-years [PY] (7/1010) in 2016 to 0.08/100 PY (6/7951) in 2019. No previous treatment with etanercept (odds ratio [OR] = 0.33, 95% CI: 0.14-0.80, P = 0.014) and low number of previous biologic therapies (OR = 0.67, 95% CI: 0.47, 0.94, P = 0.021) were significantly associated with new IBD. CONCLUSION: The incidence of new IBD was low and decreased from 2016 to 2019. The outcome was favourable in 24 out of 31 patients, but two patients died.
引用
- Letarouilly JG, Pham T, Pierache A, et al. New-onset inflammatory bowel diseases among IL-17 inhibitor-treated patients: results from the case-control MISSIL study. Rheumatology (Oxford). 2022. PMID: 34730790. doi:10.1093/rheumatology/keab819
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。